These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 16846475

  • 1. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
    Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT, Kessler B, Galardy P, Ploegh H, Tassone P, Hideshima T, Mitsiades C, Munshi NC, Chauhan D, Anderson KC.
    Br J Haematol; 2006 Jul; 134(2):145-56. PubMed ID: 16846475
    [Abstract] [Full Text] [Related]

  • 2. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMillin D, Miller JW, Mitsiades N.
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
    [Abstract] [Full Text] [Related]

  • 3. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
    Zhao X, Qiu W, Kung J, Zhao X, Peng X, Yegappan M, Yen-Lieberman B, Hsi ED.
    Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
    [Abstract] [Full Text] [Related]

  • 4. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
    Strauss SJ, Higginbottom K, Jüliger S, Maharaj L, Allen P, Schenkein D, Lister TA, Joel SP.
    Cancer Res; 2007 Mar 15; 67(6):2783-90. PubMed ID: 17363600
    [Abstract] [Full Text] [Related]

  • 5. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rötzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM, Sezer O.
    Eur J Haematol; 2008 Feb 15; 80(2):133-42. PubMed ID: 18005386
    [Abstract] [Full Text] [Related]

  • 6. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD.
    J Natl Cancer Inst; 2010 Jul 21; 102(14):1069-82. PubMed ID: 20505154
    [Abstract] [Full Text] [Related]

  • 7. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
    Pahler JC, Ruiz S, Niemer I, Calvert LR, Andreeff M, Keating M, Faderl S, McConkey DJ.
    Clin Cancer Res; 2003 Oct 01; 9(12):4570-7. PubMed ID: 14555532
    [Abstract] [Full Text] [Related]

  • 8. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL.
    Cancer Res; 2008 Aug 15; 68(16):6698-707. PubMed ID: 18701494
    [Abstract] [Full Text] [Related]

  • 9. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.
    Lü S, Yang J, Song X, Gong S, Zhou H, Guo L, Song N, Bao X, Chen P, Wang J.
    J Pharmacol Exp Ther; 2008 Aug 15; 326(2):423-31. PubMed ID: 18502982
    [Abstract] [Full Text] [Related]

  • 10. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.
    Lauricella M, Emanuele S, D'Anneo A, Calvaruso G, Vassallo B, Carlisi D, Portanova P, Vento R, Tesoriere G.
    Apoptosis; 2006 Apr 15; 11(4):607-25. PubMed ID: 16528474
    [Abstract] [Full Text] [Related]

  • 11. Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors.
    Chu S, Alexiadis M, Fuller PJ.
    Reprod Sci; 2009 Apr 15; 16(4):397-407. PubMed ID: 19087975
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS, Corringham RE, Zaki MH, Nemeth JA, Orlowski RZ.
    Clin Cancer Res; 2007 Nov 01; 13(21):6469-78. PubMed ID: 17975159
    [Abstract] [Full Text] [Related]

  • 13. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
    Balsas P, Galán-Malo P, Marzo I, Naval J.
    Leuk Res; 2012 Feb 01; 36(2):212-8. PubMed ID: 21978467
    [Abstract] [Full Text] [Related]

  • 14. In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells.
    Duechler M, Linke A, Cebula B, Shehata M, Schwarzmeier JD, Robak T, Smolewski P.
    Eur J Haematol; 2005 May 01; 74(5):407-17. PubMed ID: 15813915
    [Abstract] [Full Text] [Related]

  • 15. BAG3 gene silencing sensitizes leukemic cells to Bortezomib-induced apoptosis.
    Liu P, Xu B, Li J, Lu H.
    FEBS Lett; 2009 Jan 22; 583(2):401-6. PubMed ID: 19111544
    [Abstract] [Full Text] [Related]

  • 16. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E, Alvarez-Fernández S, Maiso P, Martín-Sánchez J, Vidriales MB, Garayoa M, Ocio EM, Montero JC, Pandiella A, San Miguel JF.
    Haematologica; 2008 Jan 22; 93(1):57-66. PubMed ID: 18166786
    [Abstract] [Full Text] [Related]

  • 17. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
    Balsas P, López-Royuela N, Galán-Malo P, Anel A, Marzo I, Naval J.
    Biochem Pharmacol; 2009 Mar 01; 77(5):804-12. PubMed ID: 19100720
    [Abstract] [Full Text] [Related]

  • 18. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
    Fujita T, Doihara H, Washio K, Ino H, Murakami M, Naito M, Shimizu N.
    Anticancer Drugs; 2007 Jul 01; 18(6):677-86. PubMed ID: 17762396
    [Abstract] [Full Text] [Related]

  • 19. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
    Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, Knight J, Starostik P, Deans J, Hernandez-Ilizaliturri FJ.
    Clin Cancer Res; 2008 Mar 01; 14(5):1561-70. PubMed ID: 18316581
    [Abstract] [Full Text] [Related]

  • 20. Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo.
    Michaelis M, Fichtner I, Behrens D, Haider W, Rothweiler F, Mack A, Cinatl J, Doerr HW, Cinatl J.
    Int J Oncol; 2006 Feb 01; 28(2):439-46. PubMed ID: 16391799
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.